Bifidobacterium longum Drug Interactions
Currently displaying a list of 351 drugs known to interact with bifidobacterium longum.
- 351 moderate drug interactions
Medications known to interact with bifidobacterium longum
Note: Showing generic names only.
A
- abatacept
- abemaciclib
- abrocitinib
- acalabrutinib
- adalimumab
- afamitresgene autoleucel
- aldesleukin
- alefacept
- alemtuzumab
- altretamine
- amoxicillin
- ampicillin
- anakinra
- anifrolumab
- anisindione
- anti-thymocyte globulin (rabbit)
- asciminib
- asparaginase escherichia coli
- atezolizumab
- atovaquone
- avacopan
- avapritinib
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- azithromycin
B
- bacampicillin
- baricitinib
- basiliximab
- belantamab mafodotin
- belatacept
- belimumab
- belinostat
- bendamustine
- benznidazole
- betamethasone
- bexarotene
- bimekizumab
- bleomycin
- blinatumomab
- bortezomib
- bosutinib
- brentuximab
- brexucabtagene autoleucel
- brigatinib
- brodalumab
- budesonide
- busulfan
C
- cabazitaxel
- canakinumab
- capecitabine
- carboplatin
- carfilzomib
- carmustine
- cefaclor
- cefadroxil
- cefdinir
- cefditoren
- cefixime
- cefpodoxime
- cefprozil
- ceftibuten
- cefuroxime
- cephalexin
- cephradine
- certolizumab
- chlorambucil
- chloramphenicol
- ciltacabtagene autoleucel
- cinoxacin
- ciprofloxacin
- cisplatin
- cladribine
- clarithromycin
- clindamycin
- clofarabine
- clofazimine
- cloxacillin
- cobimetinib
- copanlisib
- corticotropin
- cortisone
- cosibelimab
- crizotinib
- crovalimab
- cyclophosphamide
- cyclosporine
- cytarabine
D
- dacarbazine
- daclizumab
- dactinomycin
- danicopan
- dapsone
- daratumumab
- dasatinib
- daunorubicin
- daunorubicin liposomal
- decitabine
- deflazacort
- delafloxacin
- demeclocycline
- denileukin diftitox
- deucravacitinib
- deuruxolitinib
- dexamethasone
- dexrazoxane
- dicloxacillin
- dicumarol
- dimethyl fumarate
- dinutuximab
- dirithromycin
- diroximel fumarate
- docetaxel
- doxorubicin
- doxorubicin liposomal
- doxycycline
- dupilumab
- durvalumab
- duvelisib
E
- eculizumab
- efalizumab
- efgartigimod alfa
- eflornithine
- elotuzumab
- elranatamab
- emapalumab
- enfortumab vedotin
- enoxacin
- epcoritamab
- epirubicin
- eribulin
- erythromycin
- etanercept
- etoposide
- etrasimod
- everolimus
F
- fam-trastuzumab deruxtecan
- fidaxomicin
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- fluorouracil
- fosfomycin
- fruquintinib
- furazolidone
G
- gatifloxacin
- gemcitabine
- gemifloxacin
- gemtuzumab
- givinostat
- glofitamab
- golimumab
- grepafloxacin
- guselkumab
H
I
- ibritumomab
- ibrutinib
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- imatinib
- imetelstat
- inavolisib
- inebilizumab
- infliximab
- inotuzumab ozogamicin
- iobenguane I 131
- iodine i 131 tositumomab
- iptacopan
- irinotecan
- irinotecan liposomal
- isatuximab
- ixabepilone
- ixazomib
- ixekizumab
L
- lefamulin
- leflunomide
- lenalidomide
- levamisole
- levofloxacin
- lifileucel
- lincomycin
- linezolid
- lisocabtagene maraleucel
- lomefloxacin
- lomustine
- loncastuximab tesirine
- loracarbef
- lurbinectedin
- lutetium lu 177 dotatate
- lutetium lu 177 vipivotide tetraxetan
- lymphocyte immune globulin, anti-thy (equine)
M
- mechlorethamine
- melphalan
- melphalan flufenamide
- mercaptopurine
- methenamine
- methotrexate
- methylprednisolone
- metronidazole
- midostaurin
- minocycline
- mirikizumab
- mitomycin
- mitoxantrone
- mogamulizumab
- momelotinib
- monomethyl fumarate
- mosunetuzumab
- moxifloxacin
- muromonab-cd3
- mycophenolate mofetil
- mycophenolic acid
N
- nalidixic acid
- natalizumab
- naxitamab
- nelarabine
- nifurtimox
- nilotinib
- nipocalimab
- niraparib
- nitrofurantoin
- norfloxacin
O
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- ofloxacin
- olaparib
- olaratumab
- omacetaxine
- omadacycline
- osimertinib
- oxacillin
- oxaliplatin
- oxytetracycline
- ozanimod
P
- paclitaxel
- paclitaxel protein-bound
- pacritinib
- palbociclib
- panobinostat
- pazopanib
- pegaspargase
- pegcetacoplan
- pemetrexed
- penicillin v potassium
- pentostatin
- pirtobrutinib
- pivmecillinam
- plicamycin
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- pozelimab
- pralatrexate
- prednisolone
- prednisone
- procarbazine
Q
R
- ravulizumab
- revumenib
- ribociclib
- rifaximin
- rilonacept
- risankizumab
- ritlecitinib
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- rucaparib
- ruxolitinib
S
- sacituzumab govitecan
- sarecycline
- sarilumab
- satralizumab
- secnidazole
- secukinumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus protein-bound
- sparfloxacin
- spesolimab
- streptozocin
- sulfadiazine
- sulfadoxine
- sulfamethizole
- sulfamethoxazole
- sulfisoxazole
- sutimlimab
T
- tacrolimus
- tafasitamab
- talazoparib
- talquetamab
- tarlatamab
- tazemetostat
- teclistamab
- tedizolid
- telisotuzumab vedotin
- telithromycin
- temozolomide
- temsirolimus
- teniposide
- teplizumab
- teriflunomide
- tetracycline
- thalidomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tisotumab vedotin
- tocilizumab
- tofacitinib
- topotecan
- tositumomab
- trabectedin
- trastuzumab
- treosulfan
- triamcinolone
- triamcinolone ophthalmic
- trimethoprim
- trimetrexate
- troleandomycin
- trovafloxacin
U
V
- vamorolone
- vancomycin
- vedolizumab
- venetoclax
- vilobelimab
- vinblastine
- vincristine
- vincristine liposome
- vinorelbine
- voclosporin
W
Z
Report options
QR code containing a link to this page
More about bifidobacterium longum
- bifidobacterium longum consumer information
- Check interactions
- Compare alternatives
- Side effects
- Drug class: probiotics
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.